



CVP TRAINING SERIES

Office of Immunization Childhood Vaccine Program October 16, 2025

Topics Covered



RESPIRATORY SEASON ORDERING UPDATES



2025-2026 COVID-19 **VACCINES**

Respiratory Season Ordering Updates



Inventory and Ordering Controls



Inventory must be completed in the IIS within the last 14 days for order approval



Use ROQ calculator to order the right amount of vaccine/product based on doses used last year for month ordering



All orders will be reviewed for accountability, doses used last year for month ordering and any other limitations (caps, etc.)



Providers need to choose one brand of COVID-19 vaccine for each age range



COVID-19/Flu vaccines are no longer exempt from tracking on the Vaccine Loss Log


Ordering Updates

Vaccine/Product	Ordering in IIS	Under Allocation	"Pending State Approval" Status	Orders Processed Weekly On
Flu	√	✓	COB day before order processing	Daily
RSV	\checkmark	\checkmark	Tuesday	Wednesday
COVID-19	\checkmark	\checkmark	Wednesday	Thursday

- Allow for at least 3 days for order approval from time of submission for accountability checks
- Orders need to be in "pending state approval status" in the IIS by close of business the weekday before the processing day
- Orders will be pulled from the IIS at 8am on the days listed above and checked against the allocation available from the CDC

Flu Ordering

- All orders will be reviewed and compared to the amount administered for the same month last year
- Plenty of product available
- Orders may be reduced in January as demand drops off
- 2025/2026 Flu Vaccines At-a-Glance



RSV Ordering: Nirsevimab and Clesrovimab

Nirsevimab (Beyfortus)

- Monoclonal antibody
- Minimum order quantity of 5
- 50mg product (infants up to 11lbs) prioritized for birthing hospitals

Clesrovimab* (Enflonsia)

- Monoclonal antibody
- Available to order in December
- Minimum order quantity of 1
- Longer shelf-life

*Orders for clesrovimab can be placed when existing nirsevimab product is at a 2-week supply

RSV Ordering Caps: Nirsevimab and Clesrovimab

- Orders will be approved based on half the doses used for the same month last year
- If you already have a 30-day supply of product on hand your order will be denied
- Check the vaccine advertisements in the IIS before you place an order; orders will be denied if there is excess product in your region that can be transferred
- For new providers, or if no previous administration data is available, the order will be capped at 50 doses for the order (all products)

Product	Used For	Provider Type	Order Cap (Doses)
Nirsevimab 50mg Primarily for birthing hospitals	Babies up to 11lbs	Provider Office	50
		Birthing Hospital	100
Nirsevimab 100mg	Babies over 11lbs	Provider Office	100
		Birthing Hospital	50

RSV Ordering: Abrysvo

- Vaccine for pregnant people under 19
- For administration between 32-36 weeks of pregnancy from now until January 31st
- By special order only (via email) in quantities of 1
- Only order if you have an eligible patient, do not order just to have on hand
- Allow three weeks for processing and shipping

See full announcement and additional details here: Vaccine Blurbs #261: RSV

Vaccine Ordering Open Today

Ordering and Inventory **Controls Training:** PDF | FAQ

Zoom Webinar Recording

COVID-19 Ordering

- Orders will be reduced by 50% of the doses administered in the same month last year, this will change as the season progresses
- New providers, or those with no previous administration data, will be capped at 50 doses for the order
- Orders may be reduced in January as demand drops off
- All vaccines will appear in your order set, but you must select only one product for each age range
- CVP providers are required to carry and offer COVID-19 vaccines for the population they serve

See full announcement and additional details here:

Vaccine Blurbs #261: RSV Vaccine Ordering Open Today

Ordering and Inventory Controls Training:

Zoom Webinar Recording

Equity Framework

For all respiratory products: If there is not enough vaccine in allocation, orders will be reduced based on the equity framework and the allocation percentage received



Vaccine Allocation – RSV, Flu, COVID-19

Overview

This document describes the Department of Health's (DOH) vaccine allocation strategy for fall respiratory immunization products during times of limited supply. This includes a strategy to address (a) phased in or limited supply at the beginning of a season or start-up of a new product, and (b) limited supply or production issues leading to limited product availability for a specified period.

During times of limited availability of a vaccine or immunization product, our goal is to balance accessibility, supply, and demand. The goal is to implement an approach that equitably offers products across the state and mitigates disparities in access. Allocation strategies are used until supply meets

- · Allocation addresses prioritization for processing order requests; however, it does not address issues with lack of demand or lack of orders during ordering periods. Other interventions are required to increase demand for or access to products to meet equitable immunization goals.
- · Allocated amounts available for ordering and the timing of received allocations are determined by the Centers for Disease Control and Prevention (CDC) and are not at the discretion of DOH

Assumptions

- · Vaccine orders submitted to DOH will be processed weekly or bi-weekly according to the
 - o Expect to receive allocation of COVID-19 vaccine weekly to start, moving to bi-weekly.
 - o Expect to receive allocation of flu vaccine upon receipt from manufacturers until full pre-purchased amounts are received.
 - Expect to receive allocation of RSV monoclonal antibody products bi-weekly.
- · End allocation prioritization when supply meets demand and will return to routine/daily processing of orders.

KNOWLEDGE CHECK #1

COVID-19 Vaccines



FDA authorization for 2025-26 COVID-19 vaccines

Tradename	Vaccine Type	Approved for use in individuals who are:
COMIRNATY (Pfizer)	mRNA	 65 years of age and older, or 5 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
MNEXSPIKE (Moderna) *approved and available on the private market. It will not be supplied via CVP/AVP	mRNA	 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
NUVAXOVID (Novavax)	Adjuvanted	 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
SPIKEVAX (Moderna)	mRNA	 65 years of age and older, or 6 months through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

FDA guidance is not in alignment with DOH's 9/4/25 COVID-19 Vaccine Standing Order

WA DOH COVID-19 Vaccine Standing Order Guidance

Tradename	Vaccine Type	Approved for use in individuals who are:
COMIRNATY (Pfizer)	mRNA	Minimum age, 5 years
MNEXSPIKE * (Moderna) *is approved and available on the private market. It will not be supplied via CVP/AVP	mRNA	Minimum age, 12 years
NUVAXOVID (Novavax)	Adjuvanted	Minimum age, 12 years
SPIKEVAX (Moderna)	mRNA	Minimum age, 6 months

AUTHORIZATION: This standing order authorizes health care providers to administer the most updated versions of the COMIRNATY, MNEXSPIKE, SPIKEVAX, and NUVAXOVID COVID-19 vaccines to all persons aged 6 months and older, including pregnant individuals, consistent with applicable law and the terms and conditions outlined in the Standing Order.

Recommendation: COVID-19 Vaccination

WA DOH COVID-19 Vaccine Standing Order:

- COVID-19 Vaccine Standing Order(PDF) Russian - Русский (PDF) | Spanish - Español (PDF) | Vietnamese - Tiếng Việt (PDF)
- For more details, refer to the COVID-19 Vaccine Schedule for Health Care Providers (PDF)

FAQs:

- COVID-19 Vaccine Standing Order FAQ for Health Care Providers (PDF) Russian - Русский (PDF) | Spanish - Español (PDF) | Vietnamese - Tiếng Việt (PDF)
- COVID-19 Vaccine Standing Order FAQ for the Public (PDF) Russian - Русский (PDF) | Spanish - Español (PDF) | Vietnamese - Tiếng Việt (PDF)

Stop Using 2024-2025 COVID-19 Vaccines

August 27, 2025: The FDA revoked the Emergency Use Authorization (EUA) for Novavax, Moderna and Pfizer-BioNTech COVID-19 Vaccine.

- Remove <u>all</u> 2024–2025 COVID-19 vaccines from storage, even if unexpired.
- Do not discard vaccines, they must be returned.

Children 6m-11y (EUA vaccines)	Persons 12y+	
Vaccines with revoked EUAs must no longer be administered	These products have been delisted effective August 27 by Moderna and Pfizer.	
For products administered on or after August 27, 2025, it is considered a vaccine administration error.	Stop administering the 2024–2025 vaccines	
Please reach out to wachildhoodvaccines@doh.wa.gov for assistance		

Return Remaining 2024-2025 COVID-19 Products

- Reconcile 2024–2025 COVID-19 vaccine inventory in the IIS by categorizing the vaccines as "Spoiled" with the reason noted as "Expired BUD"
 - <u>DO NOT</u> use the category "RECALL"
 - Please submit the return before inactivating the vaccine in the IIS



- After reconciling your inventory, complete the online <u>Vaccine Returns</u> process to receive a return label for these doses
- Submit a <u>Vaccine Loss Log</u> for any loss over \$2500 in one month

COVID-19 Storage and Handling

COVID-19 <u>Vaccines</u> At-a-Glance




HEALTH 2025-2026 STATE SUPPLIED COVID-19 VACCINES AT-A-GLANCE

Characteristics	Pfizer-BioNTech Adolescent/Adult (Comirnaty) Single-dose Prefilled Syringe	Pfizer-BioNTech Pediatric (Comirnaty) Single-dose Vial	Moderna* Adolescent/Adult (Spikevax) Single-dose Prefilled Syringe	Moderna Pediatric (Spikevax) <u>Single-dose</u> Prefilled Syringe	Novavax/Sanofi Adolescent/Adult (Nuvaxovid) Single-Dose Prefilled Syringe
Vial Cap/Label Color	Grey label on box and pink stripe with "DO NOT FREEZE"	Blue Cap	Blue label on box	Red label on box	Yellow label on box
Amount of Diluent	NO DILUTION	NO DILUTION	NO DILUTION	NO DILUTION	NO DILUTION
Formulation	Each syringe contains 1 dose of 0.3 mL	Each vial contains 1 dose of 0.3 mL	Each syringe contains 1 dose of 0.5 mL	Each syringe contains 1 dose of 0.25 mL	Each syringe contains 1 dose of 0.5 mL
Manufacturer	Pfizer BioNTech	Pfizer BioNTech	Moderna	Moderna	Sanofi
CPT/CVX Codes	91320 / 309	91319 / 310	91322 / 312	91321 / 311	91304 / 313
NDC Number	00069-2528-10	0069-2501-10	80777-0112-96	80777-0113-80	80631-0207-10
Age – Licensure	12+ years	5-11 years	12+ years	6 months-11 years	12+ years
Storage: Unpunctured Vials Freezer	DO NOT STORE IN REGULAR FREEZER	DO NOT STORE IN REGULAR FREEZER	-50°C and -15°C (-58°F and 5°F) until expiration date	-50°C and -15°C (-58°F and 5°F) until expiration date	DO NOT FREEZE
Storage: Unpunctured Vials Ultracold Freezer	DO NOT STORE IN ULTRA- COLD FREEZER	-90°C and -60°C (-130°F and -76°F) until expiration date	N/A	N/A	N/A
Storage: Unpunctured Vials/Prefilled Syringes Refrigerator	2°C to 8°C (36°F to 46°F) until expiration	2°C and 8°C (36°F and 46°F) up to 10 weeks	2°C and 8°C (36°F and 46°F) up to 60 days	2°C and 8°C (36°F and 46°F) up to 60 days	2°C to 8°C (36°F to 46°F) until expiration
Storage: Unpunctured Vials OR Prefilled-Syringe Room Temp	Up to 12 hours	Up to 12 hours	Up to 12 hours	Up to 12 hours	N/A
Storage: Punctured Vials	N/A	N/A	N/A	N/A	N/A

^{*}Available to order through AVP and CVP


Ultra Cold Storage Considerations

- Use a DDL with an air probe or probe designed specifically for ultra cold temperatures
- Use the Ultra-Cold
 Temperature Monitoring
 Log to record
 temperatures
 <u>Fahrenheit</u> & <u>Celsius</u>



DOH 348-988 September 2023 To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email civil.rights@doh.wa.gov.

Temperature Excursion Guide



What is a Beyond Use Date (BUD)?

The Beyond Use Date (BUD) replaces the manufacturer's expiration date and should be noted on the label along with the initials of the person making the calculation

- DO NOT use vaccine after the beyond use date or expiration date, whichever comes first
- Examples of when a vaccine may need a BUD include:
 - Moving vaccine from ultra-cold storage or standard freezer to refrigerator, or to room temp
 - Reconstituted vaccines
 - Multidose vials that are punctured
 - Manufacturer-shortened expiration dates
- Providers are required to label/clearly mark vaccine vials/boxes to indicate BUD.
- Helpful CDC beyond use date resources:
 - Beyond Use Date Labels (PDF)
 - What is a Vaccine Beyond-Use Date? (CDC Video)
 - The Difference Between a Vaccine Expiration Date and Beyond-Use Date (CDC Video)

Beyond Use Date(BUD) and Vaccine Loss

- Never change the expiration date for COVID-19 vaccines to the Beyond Use Date in the IIS
- When COVID-19 vaccine has an expired BUD date, remove the vaccine from your storage unit and adjust the doses out of your inventory using the category Spoiled and reason Expired BUD



- After reconciliation, follow the <u>vaccine return</u> process.
- All COVID-19 vaccine loss (expired, spoiled and wasted) must be accounted for in the IIS and all expired & spoiled vaccine must be returned (except punctured multi-dose vials)

2025-2026 State-Supplied COVID-19 Vaccines

Childhood Vaccine Program COVID-19 Products

Pfizer:

Comirnaty Pediatric, 5-11 years Single-dose vial	Comirnaty Adolescent 12+/Adult Pre-Filled syringe	
Blue Cap/Label	COVID-19 Vaccine, mRNA COMBRATY COMBRAT	
2025-2026 Formula	2025-2026 Formula	

Moderna:

Spikevax Pediatric, 6 months-11 years Pre-filled syringe	Spikevax Adolescent 12+/Adult Pre-Filled syringe	
Red Label	Blue Label	
2025-2026 Formula	2025-2026 Formula	

Novavax/Sanofi:



Shelf Life and Storage Expectations

Moderna:

- Initial dating 3–6 months
- Shelf life may shorten as the season progresses

Pfizer:

- 12y+ doses: Refrigerated, ≥12 weeks shelf life
- 5–11y doses: Ultracold, ≥3 months shelf life (when stored ultracold)
- Shelf life may be shorter later in the season

Sanofi/Novavax:

- Expiration December 31, 2025
- Sanofi is working with FDA on a shelf-life extension

Moderna Spikevax COVID-19 Vaccines

Freezer or Refrigerator (with BUD):

Spikevax Pediatric, 6 months-11 years Pre-filled syringe	Spikevax Adolescent 12+/Adult Pre-Filled syringe
Red Label	Blue Label
2025-2026 Formula	2025-2026 Formula

- Can be stored in a regular freezer until expiration
- All vaccine moved from a regular freezer to refrigerator has up to a 60-day Beyond Use Date
- To avoid waste, store vaccine in the freezer and thaw doses in the fridge as needed

Pfizer Comirnaty COVID-19 Vaccines

Ultra-Cold Storage or Refrigerator (with BUD):



- Can be stored in an ultra-cold freezer until expiration
- Do not store in regular freezer
- All vaccine moved from an ultra-cold freezer to refrigerator has up to a 10-week Beyond Use Date (BUD)
- To avoid waste, store vaccine in an ultra-cold freezer and thaw doses in the fridge as needed

Refrigerator:



- Do not freeze
- Store in refrigerator until expiration
- Shipped at refrigerated temps and does not ship with temperature monitor

Novavax/Sanofi Nuvaxovid COVID-19 Vaccine

Refrigerator:



✓ This vaccine is only stored in the refrigerator, <u>no</u> beyond use date label is needed

KNOWLEDGE CHECK #2

Resources

- Childhood Vaccine Program (DOH), contact wachildhoodvaccines@doh.wa.gov
- 2025/2026 Flu Vaccines At-a-Glance
- COVID-19 Vaccine Standing Order (PDF) | Standing Order FAQ for Health Care Providers (PDF)
- 2025-2026 State Supplied COVID-19 Vaccines At-a-Glance
- Vaccine Return Guide
- Vaccine Loss Log
- Beyond Use Date Tracking Labels (CDC)
- Vaccine Storage and Handling Toolkit (CDC)
- Vaccine Temperature Excursion Guide (DOH)
- Training Links:
 - What is a Vaccine Beyond-Use Date or Time? (CDC Video)
 - The Difference Between a Vaccine Expiration Date and Beyond-Use Date or Time (CDC Video)

Future Training Topics

November 13th at Noon: What to Do in a Power Outage

Please send suggestions for future topics to:

WAChildhoodVaccines@doh.wa.gov

Questions?

Childhood Vaccine Program Main Contact Information

WAChildhoodVaccines@doh.wa.gov

Phone: (360)236-2829

Fax: (360)236-3811



To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email doh.information@doh.wa.gov.